ClinicalTrials.gg
RecruitingNCT04775745Updated Feb 13, 2026

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

A Phase 1 interventional study of LP-168 and LP-168 in CLL/SLL, Waldenstrom Macroglobulinemia and Follicular Lymphoma, sponsored by Newave Pharmaceutical Inc. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by Newave Pharmaceutical Inc (part of Lupeng Pharmaceutical Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 419 studies in Waldenstrom Macroglobulinemia with a site in United States — 34 open to participants now, 57 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · United States.

Planned enrollment
98th of 365
60 · median 37
Started
2021
with 11 others
Phase 1
140 of 419
13 open now
Primary completion
2027-12
later than 33 of 54 live
Registered
380th of 419
by date

Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, this one is the 98th largest by planned enrollment of the 365 interventional ones that give a count, is one of 12 that started in 2021, is one of 140 in phase 1, reaches primary completion later than 33 of the 54 other live ones, and was the 380th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 62 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

34 of the 419 studies in Waldenstrom Macroglobulinemia with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Waldenstrom Macroglobulinemia studies recruiting now, 44 (92%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 419 studies in Waldenstrom Macroglobulinemia with a site in United States, or all of them as a file.
02

Study summary

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

Read the detailed description

The primary objectives for the study are to assess the safety and tolerability profile, determine the maximum tolerated dose (MTD), and/or the recommended Phase 2 dose (RP2D) of LP-168 administered once or twice daily as a single agent dosed orally in adult subjects with relapsed/refractory B-cell Malignancies (CLL/SLL, WM, FL, MCL, MZL, DLBCL, HCL); and to characterize the pharmacokinetics (PK) profile of LP-168 in adult subjects with relapsed/refractory B-cell Malignancies (CLL/SLL, WM, FL, MCL, MZL, DLBCL, HCL).

Secondary objectives of the study are to evaluate preliminary efficacy regarding the effect of LP-168 on progression-free survival (PFS), objective response rate (ORR), and duration of response (DOR) in adult subjects with relapsed/refractory B-cell Malignancies (CLL/SLL, WM, FL, MCL, MZL, DLBCL, HCL).

Once the MTD is declared and the RP2D is established, additional subjects will be enrolled in a cohort expansion phase (Phase 1b).

03

Conditions studied

  • CLL/SLL
  • Waldenstrom Macroglobulinemia
  • Follicular Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Hairy Cell Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A subject will be eligible for study participation if he/she meets the following criteria:

  • Subjects are eligible with B-cell , WM, FL, MCL, MZL, DLBCL, HCL, CLL, SLL, based upon 2016 updated WHO classification. Those subjects with WM, FL, MCL, DLBCL, or HCL must have received at least 2 prior systemic therapies.
  • Low-grade B-cell lymphomas as follicular Grade 1, 2, or 3A, marginal zone or small lymphocytic lymphoma.
  • Subject must have adequate coagulation, renal, and hepatic function, per local laboratory reference ranges at Screening as follows:

    • (APTT) and prothrombin time (PT) not to exceed 1.5 ×
    • Calculated (CrCl) ≥ 60 mL/min using 24-hour CrCl OR Cockcroft-Gault formula.
    • (AST) and alanine aminotransferase (ALT) ≤ 1.5 ×ULN; ≤ 1.5 × ULN (except subjects with Gilbert's Syndrome, who may have a bilirubin > 1.5 × ULN, per discussion between the Investigator and the Medical Monitor).
  • Subjects must have adequate bone marrow independent of growth factor support per local laboratory reference range at screening as follows:

    • (ANC) ≥1000/uL;
    • An exception is for subjects with an ANC\<1000/uL and bone marrow heavily infiltrated with underlying disease (approximately 60% or more) may use growth factor to achieve the ANC eligibility criteria per discussion between the Investigator and the Medical Monitor.
    • count ≥ 50,000/µL - OR - Platelet count ≥ 20,000/ µL if thrombocytopenia is clearly due to CLL disease under study (per Investigator discretion)
    • ≥8.0g/dL, and can be achieved by transfusion

Exclusion criteria

Exclusion Criteria:

A subject will not be eligible for study participation if he/she meets any of the following criteria.

  • Subject has received any of the following therapies within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug, or has not recovered to ≤ Grade 1 adverse effect(s)/toxicity(s) of the previous therapy (other than alopecia):

    • Any anti-cancer therapy including chemotherapy, biologic or immunotherapy, radiotherapy, etc;
    • Any therapy, including targeted small molecule agents.
    • For CLL subjects who come off BCR antagonists (BTK inhibitors, PI3K inhibitors, etc.) treatment, allow for 2 days as these subjects progress quickly after treatment discontinuation and then remain eligible ( may be given during these two days to allow disease control).
  • Subjects who require immediate cytoreduction. However, subjects may receive up to two days of steroids for symptoms of impending organ impairment and remain eligible.
  • Subject has received the following medications or therapies within 7 days prior to the first dose of study drug:

    • Steroid therapy (at dosages equivalent to prednisone >20 mg/day) for anti-neoplastic intent (except as noted in exclusion criteria #3);
    • Cytochrome P450, family 3, subfamily A () strong inhibitors and strong CYP2C8 inducers/inhibitors.
    • Potent CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, and St. John's wort.
  • Subjects require treatment with systemic acid-reducing agents including H-2-receptor antagonists and proton pump inhibitors with the following exceptions:

    • Proton pump inhibitors should be discontinued at least 7 days prior and held throughout the study
    • If concurrent use of an H2 blocking agent is necessary, it must be administered only between 2 and 3 hours after the dose of LP-168. If not taken during this time, the dose of H2 blocking agents should not be taken again until 2-3 hours after the next dose of LP-168.
    • If concurrent use of a local antacid is necessary, it must be administered 2 or more hours before and/or 2 or more hours after the dose of LP-168.
  • Subject has significant screening (ECG) abnormalities including. 2nd degree AV block type II 3rd degree block, Grade 2 or higher bradycardia, and interval (QTc) ≥ 480ms.
  • Serum amylase > 1.5 × or serum lipase > 1.5 × ULN.
  • Subject has any history of Richter's transformation for Phase 1a portion of the trial.
  • Subjects who have undergone /allogeneic hematopoietic stem cell transplantation (HSCT) therapy within 90 days of the first dose of LP-168, or patients on therapy post-HSCT at the time of Screening, or currently with clinically significant (GVHD) as per treating physician (Patients in relapse after allogeneic transplantation must be off treatment with systemic immunosuppressive agents for at least 4 weeks. The use of topical steroids and/or up to 20 mg/day prednisone or equivalent systemic steroids for ongoing GVHD is permitted.
  • Subject has a history of other active other than B-cell malignancies within the past 3 years prior to study entry, with the exception of:

    • Adequately treated in situ carcinoma of the cervix uteri;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
  • Subject requires anticoagulation with Warfarin.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Dose Escalation Phase

    Three to six subjects per treatment cohort will be assigned to receive sequentially higher oral doses of LP-168 on a once or twice daily schedule for 28 days, starting at a dose of 100 mg/day.

    Drug: LP-168

  • Experimental
    Dose Expansion Phase

    Additional subjects will be recruited to further explore the safety, tolerability, PK, and efficacy in specific subject subgroups.

    Drug: LP-168

Interventions

  • DrugLP-168

    For the dose escalation phase, LP-168 will be given once or twice daily at the following dose levels:100 mg QD,150 mg QD, 100 mg BID, 300 mg QD, 150 mg BID, 450 mg QD, 225 mg BID, 600 mg QD, 800 mg QD, and 1000 mg QD.

  • DrugLP-168

    For the dose expansion phase, subjects will receive once or twice daily dose of LP-168 at the Recommended Phase 2 Dose (RP2D). The RP2D may be as high as the MTD and will be determined following evaluation of Phase I Dose Escalation results.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    When more than 1 DLT occurs in ≤ 6 subjects in a dosing cohort, dose escalation will be stopped and this dose level will be identified as the non-tolerated dose. Doses between the non-tolerated dose and the preceding lower dose, where ≤ 1 DLT occurred, may be explored to more precisely define the MTD.

    Time frame: Up to 24 months, each cycle is 28 days

  2. Recommended Phase 2 dose (RP2D)

    The RP2D may be as high as the MTD or a lower dose and will be selected in discussion with the Investigators and the Sponsor based on longer term safety data, preliminary efficacy data, and PK data.

    Time frame: Up to 24 months, each cycle is 28 days

  3. Pharmacokinetic (PK) profile of LP-168

    Maximum Plasma Concentration \[Cmax\]

    Time frame: At Cycle 1: Day 1, Day 2, Day 8, Day 9, Day 15, Day 22, Day 28; At Cycle 3: Day 28; At Cycle 6 Day 28; (each cycle is 28 days)

  4. Pharmacokinetic (PK) profile of LP-168

    Area Under the Curve \[AUC\]

    Time frame: At Cycle 1: Day 1, Day 2, Day 8, Day 9, Day 15, Day 22, Day 28; At Cycle 3: Day 28; At Cycle 6 Day 28; (each cycle is 28 days

  5. Pharmacokinetic (PK) profile of LP-168

    Time at Maximum Concentration \[Tmax\]

    Time frame: At Cycle 1: Day 1, Day 2, Day 8, Day 9, Day 15, Day 22, Day 28; At Cycle 3: Day 28; At Cycle 6 Day 28; (each cycle is 28 days

Secondary outcomes

  1. Progression-Free Survival (PFS)

    PFS is measured from the time of first study drug administration until the first date that recurrent or progressive disease is objectively documented.

    Time frame: Up to 24 months, each cycle is 28 days

  2. Objective Response Rate (ORR)

    ORR is defined as the sum of complete response (CR) and partial remission rates.

    Time frame: Up to 24 months, each cycle is 28 days

  3. Duration of Response (DOR)

    The duration of overall response is measured from the time measurement criteria are met for CR or PR (which is first recorded) until the first date that recurrent or progressive disease is objectively documented

    Time frame: Up to 24 months, each cycle is 28 days

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2027, 77 months after the start.

Of 50 phase 1 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 80. This study's planned 77 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2021
First posted
Mar 1, 2021
StartActual
Jul 19, 2021
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04775745
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Jul 19, 2021
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Anna Chen, MD, PhD
Contact
yu@newavepharma.com
(206) 335-3820
Stephen Anthony, DO
Contact
s.anthony@newavepharma.com

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocbrutinib

Start the discussion